CLINICAL RESEARCH
Uterine sarcomas: clinical characteristics, management, and outcomes – a single centre’s experience
 
More details
Hide details
 
Submission date: 2018-09-19
 
 
Final revision date: 2018-10-29
 
 
Acceptance date: 2018-12-03
 
 
Publication date: 2018-12-17
 
 
Arch Med Sci Civil Dis 2018;3(1):184-189
 
KEYWORDS
TOPICS
ABSTRACT
Introduction:
The purpose of the present study is to evaluate the clinical presentation, histopathologic pattern and outcome of uterine sarcomas in a single institution of gynaecological oncology.

Material and methods:
The database of the Gynecologic Oncology Department of the hospital was used to identify patients diagnosed with pathological uterine sarcoma treated between January 1, 2004, and December 31, 2015. We collected clinicopathological data to evaluate factors that are important for overall survival (OS).

Results:
A total of 54 cases were included in the analysis: 25 uterine leiomyosarcomas (LMS), 19 carcinosarcomas (CS) and nine endometrial stromal sarcomas (ESS). The mean age was 53.8 years for LMS, 62.1 years for CS. Disease recurrence occurred in 13 (24.0%) patients. The recurrent disease occurred in the pelvis in nine patients, but it was characterised by distant metastases (liver or mediastinal lymph nodes) in the other four patients Having had a lymphadenectomy and adjuvant chemotherapy for CS and advanced stage for LMS were the only factors for which a significant difference in OS was observed (p = 0.035, p = 0.006 and p = 0.04, respectively). In contrast, for CS, only not having adjuvant chemotherapy showed a significant association with poor disease free survival.

Conclusions:
Lymphadenectomy and adjuvant chemotherapy had a significant impact on OS for CS, and advanced stage was the only independent predictor of OS for LMS.

 
REFERENCES (21)
1.
Sharma DN, Rath GK, Kumar S, et al. Clinical outcome of patients with uterine sarcomas. J Cancer Res Ther 2011; 7: 270-4.
 
2.
D’Angelo E, Prat J. Uterine sarcomas: a review. Gynecol Oncol 2010; 116: 131-9.
 
3.
Naaman Y, Shveiky D, Ben-Shachar I, Shushan A, Mejia-Gomez J, Benshushan A. Uterine sarcoma: prognostic factors and treatment evaluation. IMAJ 2011; 13: 76-9.
 
4.
Durnali A, Tokluoğlu S, Özdemir N, et al. Prognostic factors and treatment outcomes in 93 patients with uterine sarcoma from 4 centers in Turkey. Asian Pac J Cancer Prev 2012; 13: 1935-41.
 
5.
Nassar OA, AbdulMoaty SB, Khalil e-SA, El-Taher MM, El Najjar M. Outcome and prognostic factors of uterine sarcoma in 59 patients: single institutional results. J Egypt Natl Canc Inst 2010; 22: 113-22.
 
6.
Livi L, Paiar F, Shah N, et al. Uterine sarcoma: twenty-seven years of experience. Int J Radiat Oncol Biol Phys 2003; 57: 1366-73.
 
7.
Park JY, Kim DY, Suh DS, et al. Prognostic factors and treatment outcomes of patients with uterine sarcoma: analysis of 127 patients at a single institution, 1989-2007. J Cancer Res Clin Oncol 2008; 134: 1277-87.
 
8.
Prat J. FIGO staging for uterine sarcomas. Int J Gynaecol Obstet 2009; 104: 177-8.
 
9.
Shah JP, Bryant CS, Kumar S. Lymphadenectomy and ovarian preservation in low-grade endometrial stromal sarcoma. Obstet Gynecol 2008; 112: 1102-3.
 
10.
Wright JD, Seshan VE, ShahMet. The role of radiation in improving survival for early-stage carcinosarcoma and leiomyosarcoma. Am J Obstet Gynecol 2008; 199: 536.e1-8.
 
11.
Wu TI, Yen TZ, Lai CH. Clinical presentation and diagnosis of uterine sarcoma, including imaging. Best Pract Res Clin Obstet Gynaecol 2011; 25: 681-9.
 
12.
Garcia-Martinez E, Prefasi LE, Garcia-Donas J, Escolar-Perez PP, Pastor F, Gonzalez-Martin A. Current management of uterine sarcomas. Clin Transl Oncol 2011; 13: 307-14.
 
13.
Vorgias G, Fotiou S. The role of lymphadenectomy in uterine carcinosarcomas (malignant mixed Mullerian tumours): a critical literature review. Arch Gynecol Obstet 2010; 282: 659-64.
 
14.
Nemani D, Mitra N, Guo M, Lin L. Assessing the effects of lymphadenectomy and radiation therapy in patients with uterine carcinosarcoma: a SEER analysis. Gynecol Oncol 2008; 111: 82-8.
 
15.
Ducie JA, Leitao Jr MM. The role of adjuvant therapy in uterine leiomyosarcoma. Expert Rev Anticancer Ther 2016; 16: 45-55.
 
16.
Denschlag D, Thiel FC, Ackermann S, et al. Sarcoma of the uterus. Guideline of the DGGG. Geburtshilfe Frauenheilkd 2015; 75: 1028-42.
 
17.
Menczer J, Levy T, Piura B, et al. A comparison between different postoperative treatment modalities of uterine carcinosarcoma. Gynecol Oncol 2005; 97: 166-70.
 
18.
Mancari R, Signorelli M, Gadducci A, et al. Adjuvant chemotherapy in stage I-II uterine leiomyosarcoma: a multicentric retrospective study of 140 patients. Gynecol Oncol 2014; 133: 531-6.
 
19.
Chan JK, Kawar NM, Shin JY, et al. Endometrial stromal sarcoma: a population-based analysis. Br J Cancer 2008; 99: 1210-5.
 
20.
Ramondetta LM, Johnson AJ, Sun CC, et al. Phase 2 trial of mifepristone (RU-486) in advanced or recurrent endometrioid adenocarcinoma or low-grade endometrial stromal sarcoma. Cancer 2009; 115: 1867-74.
 
21.
Abeler VM, Røyne O, Thoresen S, Danielsen HE, Nesland JM, Kristensen GB. Uterine sarcomas in Norway. A histopathological and prognostic survey of a total population from 1970 to 2000 including 419 patients. Histopathology 2009; 54: 355-64.
 
ISSN:2451-0637
Journals System - logo
Scroll to top